ArticleAmerican journal of translational research2017
Wedelolactone from Eclipta alba inhibits lipopolysaccharide-enhanced cell proliferation of human renal mesangial cells via NF-κB signaling pathway.
Article in American journal of translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Wedelolactone, a natural coumestan with multiple pharmacological effects.Frontiers in pharmacology · 2025Review
- Nephroprotective effects of substances of medicine food homology and traditional Chinese medicine phytochemicals against acute kidney injury.Frontiers in pharmacology · 2025Review
- UPLC-QTOF-MS-based lipidomic study of wedelolactone in acute colitis mice induced by dextran sulfate sodium.Heliyon · 2023Article
- The potential role of herbal extract Wedelolactone for treating particle-induced osteolysis: an in vivo study.Journal of orthopaedic surgery and research · 2022Article
- Review
- Wedelolactone facilitates Ser/Thr phosphorylation of NLRP3 dependent on PKA signalling to block inflammasome activation and pyroptosis.Cell proliferation · 2020Article
- Article
- Antidiabetic Activity of Gold Nanoparticles Synthesized Using Wedelolactone in RIN-5F Cell Line.Antioxidants (Basel, Switzerland) · 2019Article
- Development and Validation of an Ultra-Performance Liquid Chromatography Method for the Determination of Wedelolactone in Rat Plasma and its Application in a Pharmacokinetic Study.Molecules (Basel, Switzerland) · 2019Article
- Celastrol attenuates ox-LDL-induced mesangial cell proliferation via suppressing NLRP3 inflammasome activation.Cell death discovery · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesangial cells of glomerulus which could produce and degrade several ECMs, take part in the repair and update of mesangial matrix and GBM, regulate glomerular filtration rate, secret cytokines and phagocytose immune complexes contribute a lot to physiological functions and pathological reactions of glomerular. There inflammation response of abnormal proliferation induced by LPS could lead to renal damage. Herein, wedelolactone, an active chemical constituent extracted from leaves of Eclipta alba, was used to explore if it could be an effective inhibitor of the proliferative response of HRMCs. The effects of different concentration wedelolactone on the secretion of cytokines, cell viability and NF-κB pathway were all detected by qPCR, western blotting and ELISA. The results indicated that wedelolactone could inhibit the abnormal proliferation of HRMCs via regulating the activity of several key members of NF-κB signaling pathway.
Indexed as
Identifiers
28559966PMC5446498W2718853269What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.